Sign Out
Sitagliptin (Trevia) is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control as: Monotherapy.
Dual Therapy: In combination with metformin HCl or with a sulphonylurea or with a PPARγ agonist (i.e., thiazolidinediones) when the treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Triple Therapy: In combination with metformin HCl and a sulphonylurea or with metformin HCl and a PPARγ (i.e., thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control.
Combination with Insulin.
Continue with Google